MyFinsight
Home
Blog
About
Net change in cash,
cash equivalents and...
-$10,627K
(-167.90%↓ Y/Y)
Change in fair value of
contingent consideration
$2,284K
(-37.99%↓ Y/Y)
Depreciation and
amortization expense
$665K
(-36.24%↓ Y/Y)
Stock-based compensation
$661K
(-32.34%↓ Y/Y)
Inventories
-$175K
(-161.84%↓ Y/Y)
Unrealized foreign
currency losses
-$12K
Equity compensation
for bonus awards and...
$8K
(-90.91%↓ Y/Y)
Proceeds from exercise of
stock options
$10K
Net cash used in
operating activities
-$9,268K
(23.64%↑ Y/Y)
Net cash used in
investing activities
-$779K
(-18.75%↓ Y/Y)
Net cash provided by
financing activities
-$564K
(-101.98%↓ Y/Y)
Effect of exchange rate
changes on cash and cash...
-$16K
Canceled cashflow
$3,805K
Canceled cashflow
$10K
Net loss
-$11,260K
(31.40%↑ Y/Y)
Machinery and equipment
purchases, and...
$779K
(18.75%↑ Y/Y)
Taxes paid related to
net share...
$237K
Financing costs to issue
common shares
$185K
(-62.01%↓ Y/Y)
Repayment of financing
lease obligations
$152K
(-28.30%↓ Y/Y)
Accounts payable and
accrued liabilities
-$1,105K
(47.03%↑ Y/Y)
Prepaid expenses and
other assets
$589K
(211.64%↑ Y/Y)
Operating lease assets and
liabilities
-$84K
(-29.23%↓ Y/Y)
Accounts receivable
$35K
(103.18%↑ Y/Y)
Back
Back
Cash Flow
Insight Molecular Diagnostics Inc. (IMDX)
Insight Molecular Diagnostics Inc. (IMDX)
source: myfinsight.com